Skip to main content
Clinical Trials/NL-OMON53345
NL-OMON53345
Recruiting
N/A

Development of minimally invasive methodology for diabetyping to personalise treatment to realise remission and reversal of type 2 diabetes. - 2DIAREM

TNO0 sites57 target enrollmentTBD

Overview

Phase
N/A
Intervention
Not specified
Conditions
Not specified
Sponsor
TNO
Enrollment
57
Status
Recruiting
Last Updated
last year

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
last year
Study Type
Observational invasive

Investigators

Sponsor
TNO

Eligibility Criteria

Inclusion Criteria

  • \- \- Diagnosed with (pre)diabetes type 2;
  • o BMI \>\=27 kg/m2, including a heterogenous group of people with
  • overweight/prediabetes (without glucose lowering medication), and/or type 2
  • diabetes with or without glucose lowering medication.
  • \- Aged 40 years or older
  • \- Able and willing to sign the informed consent form
  • \- Willing to comply with all study procedures

Exclusion Criteria

  • \- Type 1 diabetes
  • \- Latent Autoimmune Diabetes (LADA)
  • \- Skin allergy, eczema or known sensitivity for adhesives
  • \- History of bariatric weight loss surgery
  • \- Planned (bariatric) surgery during the 3 weeks monitoring period with the CGM
  • \- Active cancer or chemotherapy or radiation within 2 years prior to
  • participation
  • \- A condition that would need an MRI during the 3 weeks monitoring period with
  • \- Planned holiday during the 3 week GCM monitoring period
  • \- (Night)shiftworkers

Outcomes

Primary Outcomes

Not specified

Similar Trials